title: [Future Therapeutic Targets in Management of Autoimmune Skin Diseases].
abstract: Pemphigus is a severe, potentially fatal bullous skin disease, caused by desmoglein autoantibody production and immune-mediated regulation of T-cells subsets. Conventional therapy including systemic corticosteroids with or without other immunosupressants causes numerous adverse effects and becomes inefficient in refractory patients. In this work, the authors showed a modern view on the pathogenesis ofpemphigus. This article describes the detailed action mechanism of rituximab, a chimeric monoclonal antibody directed against CD20 antigen of B-cells. The authors conduct the results of meta-analyses of rituximab's efficiency in pemphigus patients. Moreover, in this article, the authors consider new promising treatment tions and potential targets for biological therapy of pemphigus diseases.
authors.forename: A A
authors.initials: AA
authors.lastname: Kubanova
authors.forename: A E
authors.initials: AE
authors.lastname: Karamova
authors.forename: A A
authors.initials: AA
authors.lastname: Kubanov
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D015551:Autoimmunity; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology
chemical_list: D007155:Immunologic Factors